Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bovine intestinal alkaline phosphatase (bIAP) is a dimeric, membrane-derived glycoprotein enzyme derived from the intestinal mucosa of cattle. It hydrolyzes various phosphate esters at an optimal alkaline pH and plays a key role in detoxifying lipopolysaccharides (LPS) by dephosphorylation, thereby reducing inflammation and improving survival in models of sepsis and acute inflammatory conditions. Its mechanism involves inhibition of endotoxin activity and modulation of inflammatory responses through dephosphorylation of microbial ligands such as LPS. It has been developed primarily for use in acute inflammatory conditions including systemic inflammatory response syndrome, ischemia-reperfusion injury, burns, respiratory insufficiency, and post-cardiac surgery organ injury[3][6][4]. The enzyme is also being explored for its hepatoprotective effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bovine intestinal alkaline phosphatase.